Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05737277
Other study ID # GAB-IBSPED
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date July 1, 2023

Study information

Verified date February 2023
Source Azienda Ospedaliera "Sant'Andrea"
Contact Giovanni Di Nardo, Prof
Phone 00393397267637
Email giovanni.dinardo@uniroma1.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder (FGID) characterized by recurrent episodes of defecation related abdominal pain associated with abnormal bowel habit. Several studies have reported significant alterations in the gut microbiota that may promote the development and persistence of IBS. Some Bifidobacterium species, mainly Bifidobacterium adolescentis, have a documented immunomodulatory effect and can modulate visceral hypersensitivity or improve the integrity of the intestinal epithelium barrier thorough its well-known ability to produce g-aminobutyric acid Thus, designed a randomised, double-blind, placebo-controlled, parallel-arm study evaluating the efficacy and safety of Bifidobacterium adolescentis PRL2019 on abdominal pain symptoms in pediatric patients with Irritative bowel sindorom


Description:

This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (> 4 years) with Irritative bpwel sindrome (as assessed according to the Rome IV diagnostic criteria for IBS). The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period. After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo (without the active treatment, once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period. All the subjects will be blindly allocated by means of scratch cards to one of the two treatment groups according to a computer-generated randomisation list provided by our statistician. A validated program will be used by an independent statistician to generate a randomisation list with blocks, block size = 4, pre-allocated to centres. Patients and study investigators will be blinded to the randomisation codes. The codes will be kept confidential until the end of the study when the randomisation code will be broken after the database lock. All subjects will undergo a formal clinical assessment and will be further phenotyped using validated questionnaires. Number of bowel movements per day and/or week and bowel habit characteristics, will be assessed by the Bristol stool scale. The protocol will be approved by an independent ethics committee and conducted according to the Declaration of Helsinki and the principles of good clinical practice. The trial will be registered in a public registry. The primary outcome will be the change in the abdominal pain symptoms (frequency and severity) according to validated score from baseline to the end of the treatment period. Secondary outcomes will be modifications of bowel habits and safety. Study patients Eligible patients with symptoms meeting Rome IV criteria for diagnosis of Irritative bowel sindrome will be recruited from Sant'Andrea University Hospital. Inclusion criteria will comprise a positive diagnosis of all Irritative Bowel Sindrome subtypes, at least 4 and no more of 17 years of age, negative fecal calprotectine and anti-transglutaminasi antibodies. Exclusion criteria will include the current use of nonsteroidal anti-inflammatory drugs, corticosteroids and mast cell stabilisers, the use of topical or systemic antibiotics in the last month, or the continuous use of stimulant laxatives, major abdominal surgery, inflammatory bowel disease, infectious diarrhoea, allergic diseases and other organic or psychiatric disorders. Statistical Analysis The estimated total sample size that was aimed was 96 (48 children per arm) with the power of 80% (alpha of 5%). We estimated a dropout rate of 20% and aimed to recruit 120 participants to provide at least 96 evaluable assessments. Difference between continuous variables will be assessed either by two-tailed Student t test for values with normal distribution or the MannWhitney test for non-normally distributed variables. paired samples, based on distribution, Student t test for paired samples or Wilcoxon test will be used. To compare categorical variables chi squared test will be used. The difference between study groups will be considered significant when the P value will be <0.05. Statistical analysis will be performed by using the computer software SPSS 25.0


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date July 1, 2023
Est. primary completion date May 1, 2023
Accepts healthy volunteers No
Gender All
Age group 4 Years to 17 Years
Eligibility Inclusion Criteria - IBS subtypes 4 -17 years of age, - negative fecal calprotectine - negative anti-transglutaminasi antibodies. Exclusion Criteria: - the current use of nonsteroidal anti-inflammatory drugs, corticosteroids and mast cell stabilisers, - the use of topical or systemic antibiotics in the last month, - use of stimulant laxatives, - major abdominal surgery, - inflammatory bowel disease, - infectious diarrhoea, - allergic diseases a - psychiatric disorders.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gabapral
This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS). The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period.
Placebo
This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS). The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Azienda Ospedaliera "Sant'Andrea"

Outcome

Type Measure Description Time frame Safety issue
Primary Rome IV criteria The primary outcome will be the improve in the abdominal pain symptoms (frequency and severity) according to validated score from baseline to the end of the treatment period. 2 months
Secondary bristol stool scale Secondary outcomes will be modifications of bowel habits and safety. 6 months
See also
  Status Clinical Trial Phase
Completed NCT04176822 - Designing Animated Movie for Preoperative Period N/A
Completed NCT01981954 - A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO) Phase 3
Completed NCT02199626 - SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD). Phase 4
Recruiting NCT04679792 - Postual Control in Pediatric Chiari I Malformation
Recruiting NCT06061159 - The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction Phase 4
Active, not recruiting NCT05453968 - Berotralstat Treatment in Children With Hereditary Angioedema Phase 3
Not yet recruiting NCT02182648 - Bispectral Index Guiding Etomidate Used in Children Aged 3 to 10 for Clinical Anesthesia Induction Phase 4
Active, not recruiting NCT04176640 - Quantifying Brain Injury on Computed Tomography in Hospitalized Children
Active, not recruiting NCT06146452 - Micronutrient Status in Pediatric Palliative Care
Completed NCT04041180 - Impact on the Length of Stay in Incentive Spirometry and Pain in the Decompensation of Sickle Cell Disease: .
Not yet recruiting NCT06165003 - Examination of Nurses' Use of Broselow Tape in Non-resuscitation Pediatric Emergency Department Practices N/A
Recruiting NCT02286297 - Pediatric Endotracheal Intubation During Resuscitation N/A
Unknown status NCT00613184 - Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses N/A
Recruiting NCT00265772 - Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Phase 4
Completed NCT04106063 - A New Speech, Spatial, and Qualities of Hearing Scale Short-Form for Deaf Children
Not yet recruiting NCT06376643 - Augmented Reality to Support Cardiopulmonary Resuscitation N/A
Not yet recruiting NCT05511233 - ERAS Protocol in Newborns: CARES Study N/A
Not yet recruiting NCT04127968 - Efficacy and Safety of Vitamin A Treatment for Children With Sepsis N/A
Active, not recruiting NCT04472286 - Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors
Recruiting NCT04988516 - Virtual Reality Distraction for Anxiety (VR-IMAGINE) N/A